Nitrous oxide (N2O) toxicity has serious medical sequelae affecting both the CNS and the bone marrow. Neurological effects include encephalopathy, myelopathy, and neuropathy. This results from demyelination and gliosis due to selective inhibition of vitamin B12 1. Bone marrow toxicity may lead to myelosuppression, including neutropenia and megaloblastic anemia.
N2O is an established and widely used anesthetic gas though also misused quite commonly for recreational purposes as a legal 'high'. Canisters of nitrous oxide, colloquially known as “whippets”, "nangs", or "bulbs" 5, are used commercially as a propellant for whipped cream, and are commonly abused 6.
As an end user, nitrous oxide gas is a close-to-ideal recreational agent, it is legal, inexpensive, easily accessible, and not found on standard illicit substance screens. Physiologically, its effects manifest within seconds of inspiring the gas, and its offset is just as rapid, with no after effects, such that users may continue with their regular activities only minutes post-exposure.
In the 2013/14 Crime Survey for England and Wales, it was reported that almost 8% 16 to 24 year olds had used nitrous oxide recreationally in the previous 12 months 8.
Pre-existing vitamin B12 deficiency increases risk of nitrous oxide induced toxicity 8.
The classic neurological appearance of vitamin B12 deficiency is the so-called subacute combined degeneration of the cord manifested as damage to the dorsal columns of the spinal cord, responsible for the transmission of vibratory and proprioceptive input. Peripheral neuropathy, optic atrophy, and dementia can also occur.
Neurotoxicity is secondary to the selective inhibition of vitamin B12 (hydroxocobalamin), which serves as a cofactor for methionine synthase, which is an enzyme active in folate metabolism and the formation of myelin sheath phospholipids 2,4.
Radiographic features are identical to those of subacute combined degeneration of the cord.
- T2: thoracic hyperintense signal involving the dorsal columns (inverted "V" sign), although less commonly lateral tracts of the spinal cord may also be affected; very rarely is there involvement of the anterior spinal cord
Treatment and prognosis
Treatment options include:
- halting exposure to nitrous oxide
- high dose of intramuscular vitamin B12, followed by oral supplementation
- methionine supplementation has also been used 2
Despite optimal treatment some patients are left with a permanent deficit, including lifelong paraparesis.
Although there is no risk of physical addiction, the risk of a psychological N2O habit is a clear and present danger 8.
History and etymology
Nitrous oxide gas was first synthesized in 1772 by an English theologian and chemist, Joseph Priestly, chiefly remembered historically for his discovery of oxygen. Within only a few years it was already being abused as a recreational 'high', aware of this Humphrey Davy coined the term "laughing gas" 7,8. By 1844, Horace Wells, an American dentist, had reported its usefulness as an anesthetic gas.
On imaging, the differential diagnosis includes:
- other etiologies of subacute combined degeneration of the cord
- copper deficiency myeloneuropathy: can look identical
- vitamin E deficiency: can look identical
- infectious causes
- inflammatory processes
- hereditary syndromes
- leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation: characteristically also involves the cerebral white matter and the brainstem
- Friedreich ataxia: also causes cervical cord atrophy ('thinning')
- 1. Shulman RM, Geraghty TJ, Tadros M. A case of unusual substance abuse causing myeloneuropathy. (2007) Spinal cord. 45 (4): 314-7. doi:10.1038/sj.sc.3101962 - Pubmed
- 2. Stacy CB, Di Rocco A, Gould RJ. Methionine in the treatment of nitrous-oxide-induced neuropathy and myeloneuropathy. (1992) Journal of neurology. 239 (7): 401-3. Pubmed
- 3. Healton EB, Savage DG, Brust JC, Garrett TJ, Lindenbaum J. Neurologic aspects of cobalamin deficiency. (1991) Medicine. 70 (4): 229-45. Pubmed
- 4. Weimann J. Toxicity of nitrous oxide. (2003) Best practice & research. Clinical anaesthesiology. 17 (1): 47-61. Pubmed
- 5. Begley P, Sier J. 'Nanging' out: the rise of nitrous oxide as a Sydney party drug. The Sydney Morning Herald. http://www.smh.com.au/nsw/nanging-out-the-rise-of-nitrous-oxide-as-a-sydney-party-drug-20150820-gj4ai4.html. Accessed September 2017.
- 6. Thompson AG, Leite MI, Lunn MP, Bennett DL. Whippits, nitrous oxide and the dangers of legal highs. (2015) Practical neurology. 15 (3): 207-9. doi:10.1136/practneurol-2014-001071 - Pubmed
- 7. Oussalah A, Julien M, Levy J, Hajjar O, Franczak C, Stephan C, Laugel E, Wandzel M, Filhine-Tresarrieu P, Green R, Guéant JL. Global Burden Related to Nitrous Oxide Exposure in Medical and Recreational Settings: A Systematic Review and Individual Patient Data Meta-Analysis. (2019) Journal of clinical medicine. doi:10.3390/jcm8040551 - Pubmed
- 8. Randhawa G, Bodenham A. The increasing recreational use of nitrous oxide: history revisited. (2016) British journal of anaesthesia. 116 (3): 321-4. doi:10.1093/bja/aev297 - Pubmed
Related Radiopaedia articles
Toxic and metabolic encephalopathies
- overview by region
- white matter
- grey matter
- by agent/substance
- inhaled toxins
- oral toxins
- drugs (oral or IV)
- by systemic illness
- overview by region
- by substance
- Wernicke encephalopathy (vitamin B1)
- by substance
- Kearns-Sayre syndrome
- Leigh syndrome
- mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS)
- myoclonus epilepsy with ragged red fibers (MERRF)
- mitochondrial deletion syndromes
- progressive cerebral poliodystrophy (also known as Alpers syndrome)
- trichopoliodystrophy (also known as Menkes disease)